Guardant Health, Inc. - 8-K Filing
Guardant Health reported Q1 2026 revenue of $301.7 million, up 48% YoY, driven by 36% growth in Oncology revenue to $205.0 million and 600% growth in Screening revenue to $41.6 million. The company raised full-year 2026 revenue guidance to $1.30 to $1.32 billion, up from $1.25 to $1.28 billion, with Screening revenue now expected to reach $186 to $198 million. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $GH